Synthesis of pyrazolopyrimidinones using a “one-pot” approach under microwave irradiation by Kelada, Mark et al.
1222
Synthesis of pyrazolopyrimidinones using a “one-pot”
approach under microwave irradiation
Mark Kelada1, John M. D. Walsh1, Robert W. Devine1, Patrick McArdle2
and John C. Stephens*1
Letter Open Access
Address:
1Department of Chemistry, Maynooth University, Maynooth, Co.
Kildare, Ireland and 2Department of Chemistry, National University of
Ireland Galway, Co. Galway, Ireland
Email:
John C. Stephens* - john.stephens@mu.ie
* Corresponding author
Keywords:
microwave-assisted synthesis; nitrogen-fused heterocycle; one-pot;
pyrimidinone
Beilstein J. Org. Chem. 2018, 14, 1222–1228.
doi:10.3762/bjoc.14.104
Received: 14 February 2018
Accepted: 04 May 2018
Published: 28 May 2018
Associate Editor: T. J. J. Müller
© 2018 Kelada et al.; licensee Beilstein-Institut.
License and terms: see end of document.
Abstract
A simple one-pot method for the microwave-assisted synthesis of substituted pyrazolo[1,5-a]pyrimidinones, a core scaffold in
many bioactive and pharmaceutically relevant compounds, has been established. A variety of substituents was tolerated at the 2 and
5 positions, including functionalized aryls, heterocycles, and alkyl groups.
Introduction
The pyrazolo[1,5-a]pyrimidinone is a fused nitrogen-contain-
ing heterocyclic system and is of interest due to its role as a
basic core scaffold in many bioactive and pharmaceutically
relevant compounds, as well as its structural similarity to purine
[1-4]. Pyrazolo[1,5-a]pyrimidinone derivatives have found use
in the battle against several illnesses including cancer [5], viral
infections [6-8], obesity [9], and cystic fibrosis [10] (Figure 1).
It is these pharmacological properties, coupled with the pharma-
ceutical and fine chemical industries interest in synthetic pro-
cesses that utilize cleaner and more efficient technology, which
has stimulated the search for improved synthetic procedures for
their generation.
Consequently, strategies for the synthesis of compounds of
value, such as the pyrazolo[1,5-a]pyrimidinones, that employ
one-pot syntheses and/or processes have been encouraged and
have become a major focus for many synthetic chemists [11].
As such, a convenient and general method of preparing the scaf-
fold would be of significant interest to the pharmaceutical
industry. Herein, we report such a strategy for the simple syn-
thesis of functionalized pyrazolo[1,5-a]pyrimidinones that
employs a one-pot microwave-assisted approach.
Findings
A number of synthetic approaches have been developed for the
synthesis of privileged nitrogen-fused bicyclic systems such as
the pyrazolo[3,4-b]pyridines, pyrazolo[1,5-a]pyrimidines and
pyrazolo[1,5-a]pyrimidinones [12-18]. The majority of methods
used in the generation of the pyrazolo[1,5-a]pyrimidinones
employ a two-step process, which first requires the synthesis
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Figure 1: Bioactive pyrazolo[1,5-a]pyrimidinones.
and isolation of the intermediate 5-aminopyrazoles followed by
their reaction with an appropriate β-dicarbonyl compound
[1-4,19-29]. A very recent and excellent review by Aggarwal et
al. covers the use and versatility of 5-aminopyrazoles in the
synthesis of a range of pyrazoloazines [30].
As part of a study into the development of novel biologically
active compounds based on the pyrazolopyrimidinone scaffold,
we sought to develop a simple one-pot synthesis of the
nitrogen-fused bicyclic system. In order to establish reaction
conditions for this one-pot synthesis, we began by seeking
general reaction conditions for the microwave-assisted genera-
tion of the intermediate 5-aminopyrazoles. Once established,
this methodology could be expanded to generate a one-pot syn-
thesis of pyrazolo[1,5-a]pyrimidinones.
Typical methods for preparing 5-aminopyrazoles require
conventional heating of the appropriate β-ketonitrile in the pres-
ence of a hydrazine [1-4,19-29], with Rao et al. [31] and Bagley
et al. [32] reporting microwave-assisted protocols, the former
requiring an acid catalyst. In order to conduct a solvent screen
we chose β-ketonitrile 1a as a model substrate and reacted it
with hydrazine, employing a constant temperature of 150 °C
and a reaction time of 5 min. Results from the solvent screen
can be found in Table 1, with high isolated yields of the prod-
uct 5-aminopyrazole 2a in all cases. As expected, a significant
improvement in reaction time was observed under microwave
conditions in comparison with conventional heating (Table 1,
entries 7, 8 and 9). Methanol was subsequently selected as the
solvent of choice, due to the higher yield generated and its
lower cost when compared with acetonitrile. Temperature and
time were then varied with the best combination of temperature
and time found to be 150 °C for 5 min (Table 2, entry 5).
Table 1: Solvent screen for the synthesis of 5-aminopyrazole 2a.a
Entry Heating method Solvent Yieldb %
1 MW DCM 82
2 MW toluene 83
3 MW Pet ether 88
4 MW EtOAc 92




7 MW MeOH 99
8c convent. MeOH 60
9d convent. MeOH 30
aReaction conditions: ketonitrile (0.9 mmol, 1.0 equiv), hydrazine
(1.2 mmol, 1.3 equiv), solvent (1 mL) were heated under microwave
conditions (100 W, 150 °C) for 5 min. bIsolated yield. cReaction condi-
tions: ketonitrile (0.9 mmol, 1.0 equiv), hydrazine (1.2 mmol,
1.3 equiv), solvent (1 mL) were heated under conventional heating
conditions at reflux for 17 h. dReaction conditions: ketonitrile
(0.9 mmol, 1.0 equiv), hydrazine (1.2 mmol, 1.3 equiv), solvent (1 mL)
were heated under conventional heating conditions at reflux for 5 min.
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Scheme 1: Synthesis of 5-aminopyrazoles. Reaction conditions: ketonitrile (2.0 mmol, 1.0 equiv), hydrazine (2.6 mmol, 1.3 equiv), MeOH (1 mL) were
heated under microwave conditions (100 W, 150 °C) for 5 min. Isolated yields.
Table 2: Temperature and time variations for the synthesis of
5-aminopyrazole 2a.a
Entry T (°C) Time (min) Yieldb %
1 120 40 84
2 130 30 96
3 130 5 53
4 140 20 98
5 150 5 99
aReaction conditions: ketonitrile (0.9 mmol, 1.0 equiv), hydrazine
(1.2 mmol, 1.3 equiv), MeOH (1 mL) were heated under microwave
conditions (100 W). bIsolated yield.
A substrate scope study showed that a variety of substituents is
tolerated. Aromatic groups with electron-withdrawing and elec-
tron-donating substituents at the ortho, meta and para positions
were successfully explored (Scheme 1). The heterocyclic furan
and thiophene substituents allowed generation of the desired
5-aminopyrazoles in 75% and 81% yields, respectively
(Scheme 1). Alkyl groups appeared to be less well tolerated,
where the corresponding alkyl-substituted 5-aminopyrazoles
were isolated in lower yields.
With a convenient and general microwave-assisted method for
the synthesis of the 5-aminopyrazoles in hand, we next focused
our attention on its application to the one-pot synthesis of pyra-
zolo[1,5-a]pyrimidinones.
The synthesis of pyrazolo[1,5-a]pyrimidinone 3a was chosen as
the model reaction (Scheme 2). Initial reaction conditions were
chosen to match the already developed microwave-assisted syn-
thesis of the 5-aminopyrazoles. A solution of the β-ketonitrile in
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Scheme 2: One-pot synthesis of pyrazolo[1,5-a]pyrimidinones. aReaction conditions: ketonitrile (0.9 mmol, 1.0 equiv), hydrazine (1.2 mmol,
1.3 equiv), MeOH (1 mL) were heated under microwave conditions (100 W, 150 °C) for 5 min followed by the addition of AcOH (0.5 mmol, 0.6 equiv)
and ketoester (0.9 mmol, 1.0 equiv) and heated under microwave conditions (100 W, 150 °C) for a further 2 h. bIsolated yield. cReactions conditions:
isolated aminopyrazole (0.9 mmol, 1.0 equiv), AcOH (0.5 mmol, 0.6 equiv), ketoester (0.9 mmol, 1.0 equiv) in methanol (2 mL) were heated using
conventional heating conditions at reflux for 18 h. dReactions conditions: isolated aminopyrazole (0.9 mmol, 1.0 equiv), AcOH (0.5 mmol, 0.6 equiv),
ketoester (0.9 mmol, 1.0 equiv) in methanol (2 mL) were heated using conventional heating conditions at reflux for 2 h.
methanol was treated with hydrazine and heated to 150 °C
under microwave irradiation for 5 min. The β-ketoester and
acetic acid were then simply added to the pot and the reaction
heated at the same temperature, 150 °C, under microwave irra-
diation for a further 2 h. The target pyrazolo[1,5-a]pyrimidi-
none was subsequently isolated in an overall yield of 52%.
Once more, a significant improvement was observed using
microwave conditions in comparison with conventional heating.
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Figure 2: X-ray crystal structure of pyrazolo[1,5-a]pyrimidinone 3m with ellipsoids at 50% probability.
When a mixture of previously isolated 5-aminopyrazole 2a,
β-ketoester, and acetic acid were heated under conventional
refluxing conditions for 18 h, the product pyrazolo[1,5-a]pyrim-
idinone 3a could only be isolated in a 25% yield. As expected,
heating the reaction mixture for 2 h at reflux gave a lower iso-
lated yield of 11%. A one-pot procedure under conventional
refluxing conditions was also carried out in direct comparison
with the microwave method, i.e., a solution of the β-ketonitrile
in methanol was treated with hydrazine and refluxed for 5 min.
The β-ketoester and acetic acid were then added to the pot and
the reaction refluxed for a further 2 h. A complex mixture
resulted consisting mostly of starting β-ketonitrile.
The superior performance of the microwave reaction, in terms
of yield and reaction time, could result from the higher tempera-
ture and pressure achieved. The substrate scope for the one-pot
reaction was then explored, with variations of both R1 and R2
groups at the pyrazolo[1,5-a]pyrimidinone core (Scheme 2).
Pyrazolo[1,5-a]pyrimidinones containing aromatic groups with
electron-withdrawing and electron-donating substituents at the
ortho, meta and para positions were generated, including the
multi-substituted 3n, as were those with heterocyclic furyl and
thienyl substituents (Scheme 2). Alkyl-substituted pyrazolo[1,5-
a]pyrimidinones were also synthesized using this one-pot
method (Scheme 2).
The structures of the pyrazolo[1,5-a]pyrimidinones were char-
acterized using 1H and 13C NMR spectral data, HRMS, and IR
spectroscopy. In addition, an X-ray crystal structure was ob-
tained for pyrazolo[1,5-a]pyrimidinone 3m and is shown in
Figure 2.
Conclusion
In conclusion, we have developed a new facile method for
the one-pot microwave-assisted synthesis of substituted pyra-
zolo[1,5-a]pyrimidinones, a core scaffold in many bioactive and
pharmaceutically relevant compounds. A variety of functional
groups was tolerated at the 2 and 5 positions, including functio-
nalized aryls, heterocycles, and alkyl groups. Furthermore, an
efficient and general microwave-assisted synthesis of versatile
5-aminopyrazoles is reported.
Supporting Information
CCDC-1588686 contains the crystallographic data for 3m.
The data can be obtained from The Cambridge
Crystallographic Data Centre (CCDC) via
http://www.ccdc.cam.ac.uk/data_request/cif.
Supporting Information File 1
Experimental section, NMR spectra of all synthesized
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